IBNSINA Stock Overview
Produces and sells pharmaceutical drugs in Bangladesh and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
The IBN SINA Pharmaceutical Industry PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ৳289.60 |
| 52 Week High | ৳384.80 |
| 52 Week Low | ৳223.50 |
| Beta | 0.23 |
| 1 Month Change | 4.44% |
| 3 Month Change | -16.47% |
| 1 Year Change | 1.05% |
| 3 Year Change | 6.98% |
| 5 Year Change | 32.72% |
| Change since IPO | 8,680.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBNSINA | BD Pharmaceuticals | BD Market | |
|---|---|---|---|
| 7D | 2.3% | 5.0% | 2.1% |
| 1Y | 1.0% | -24.3% | -21.0% |
Return vs Industry: IBNSINA exceeded the BD Pharmaceuticals industry which returned -24.3% over the past year.
Return vs Market: IBNSINA exceeded the BD Market which returned -21% over the past year.
Price Volatility
| IBNSINA volatility | |
|---|---|
| IBNSINA Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 7.6% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in BD Market | 9.0% |
| 10% least volatile stocks in BD Market | 3.5% |
Stable Share Price: IBNSINA has not had significant price volatility in the past 3 months compared to the BD market.
Volatility Over Time: IBNSINA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 4,200 | A. K. Sadrul Islam | www.ibnsinapharma.com |
The IBN SINA Pharmaceutical Industry PLC produces and sells pharmaceutical drugs in Bangladesh and internationally. The company provides its products in various forms, such as solid dosage forms consisting of tablets and capsules; parenteral products covering ampoules and vials; liquid dosage forms comprising syrups, solutions, suspensions, and powder for suspension (dry syrups); and sterile ophthalmic products, creams, ointments, gels, eye drops and sachet, etc. It also offers various therapeutic products, including analgesic and anti-inflammatory, anti-allergic-occular, anti-arthritis supplement, anti-asthmatic, anti-emetic, anti-fibrinolytic, anti-fungal, anti-glucoma, anti-histamine, anti-malarial, anti-melasma, anti-neuropathic, anti-protozoal, anti-spasmodic, anti-ulcerant, antibacterial, antibiotic, anticataract, anti-diabetic, antigout, anti-helmintic, antimigraine agent, antisecretory, antivertigo agent, and antiviral products. In addition, the company’s therapeutic products comprise antibiotic and steroid, antibiotic-occular, antifungal-occular, antiviral-occular, anxiolytic and antidepressant, aromatase inhibitor, bile acid, bisphosphonates, calcium supplement, cardiovascular preparation, cholinesterase inhibitor, corticosteroid, cough expectorant, dry eye syndrome, gastroprokinetic agent, haematinic/vitamin and mineral, hand rub, hormone products, intestinal anti-inflammatory, laxative, multivitamin and multi-minerals, muscle relaxant, mydriatic agents, nasal decongestant, neuroleptic, nootropic, NSAIDS, NSAIDS-occular, ORS, steroid-occular, topical, urological preparation, urinary incontinence, and sodium-glucose co-transporter inhibitor products.
The IBN SINA Pharmaceutical Industry PLC Fundamentals Summary
| IBNSINA fundamental statistics | |
|---|---|
| Market cap | ৳9.05b |
| Earnings (TTM) | ৳592.31m |
| Revenue (TTM) | ৳11.23b |
15.3x
P/E Ratio0.8x
P/S RatioIs IBNSINA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBNSINA income statement (TTM) | |
|---|---|
| Revenue | ৳11.23b |
| Cost of Revenue | ৳6.78b |
| Gross Profit | ৳4.45b |
| Other Expenses | ৳3.86b |
| Earnings | ৳592.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 18.96 |
| Gross Margin | 39.63% |
| Net Profit Margin | 5.27% |
| Debt/Equity Ratio | 44.3% |
How did IBNSINA perform over the long term?
See historical performance and comparisonDividends
2.2%
Current Dividend Yield33%
Payout RatioDoes IBNSINA pay a reliable dividends?
See IBNSINA dividend history and benchmarks| IBN SINA Pharmaceutical Industry dividend dates | |
|---|---|
| Ex Dividend Date | Oct 28 2024 |
| Dividend Pay Date | Dec 24 2024 |
| Days until Ex dividend | 55 days |
| Days until Dividend pay date | 2 days |
Does IBNSINA pay a reliable dividends?
See IBNSINA dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:29 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
The IBN SINA Pharmaceutical Industry PLC is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanay Roy | IDLC Securities Limited |